Selected micronutrients in cognitive decline prevention and therapy by Visioli, Francesco & Burgos Ramos, Emma
Selected Micronutrients in Cognitive Decline
Prevention and Therapy
Francesco Visioli2 & Emma Burgos-Ramos1
Received: 13 April 2015 /Accepted: 7 July 2015
# Springer Science+Business Media New York 2015
Abstract Population aging is a worldwide demographic
trend. Consequently, the prevalence of chronic age-related
conditions such as clinically diagnosed neurological diseases,
cognitive decline, and dementia will significantly increase in
the near future. The important role of diets and healthy life-
style as preventative of neurodegenerative diseases is widely
accepted nowadays, and it may provide preventive strategies
in very early, non-symptomatic phases of dementia well, es-
pecially because there are still no effective treatments for it. In
this article, we review the known effects of selected
micronutrients on the aging brain and we propose strategies
for dietary improvements.
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Introduction
Population aging is a worldwide demographic trend. Accord-
ing to the WHO, by 2040, the proportion of world population
aged ≥65 is believed to reach 1.3 billion (14 % of the total).
Consequently, the prevalence of chronic age-related condi-
tions such as heart problems, clinically diagnosed neurologi-
cal diseases, cognitive decline, and dementia will significantly
increase. Diets rich in fresh fruit, vegetables, and unsaturated
fats, and low in simple sugars and salt and highly processed
foods, are generally associated with a reduced risk of devel-
oping several diseases such as type 2 diabetes, cardiovascular
disease, neurodegeneration, andmany forms of cancer. Shared
risk factors for both Alzheimer’s disease (AD) and vascular
diseases such as atherosclerosis, stroke, hypertension, tran-
sient ischemic attacks, cardiac disease, and apolipoprotein
E4 (APOE e4) genotype, obesity, and diabetes play important
roles in the etiology of neurodegenerative diseases such as AD
[1]. These vascular risk factors may increase the risk for AD
by promoting inflammation, cerebral vascular disease, white
matter lesions, hippocampal sclerosis, and mitochondrial dys-
function [1]. The important role of diets and healthy lifestyle
as preventative of vascular diseases is widely accepted nowa-
days, and it may provide preventive strategies in very early,
non-symptomatic phases of dementia as well, especially be-
cause there are still no effective treatments for AD. Recent
focus is therefore on the early, asymptomatic phase of the
disease especially on the (cerebro)vascular risk factors like
atherosclerosis, hypertension, and obesity, etc., being modifi-
able via changes in lifestyle factors such as diet [2]. Recently,
the Mediterranean diet has been shown in several prospective
worldwide studies to be inversely associated with cardiovas-
cular disease (CVD) and to be a strong protective factor
against hypertension, obesity, and AD [3].
Of note, the Mediterranean diet (but also the Japanese diet
[4]) is rich in micronutrients that derive from plant foods. In
this respect, it has been suggested that adequate intakes of
micronutrients, either consequent to a correct diet or through
supplementation, might afford the elderly protection from
neurodegeneration. In the cardiovascular realm, this has been
referred to as the Bmetabolic tune-up,^ which should result in
a marked increase in health at little cost [5]. In this article, we
review the known effects of micronutrients on the aging brain
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and remark that this is a subject worth addressing in preven-
tive medicine. Even though long-chain polyunsaturated fatty
acids such as docosahexaenoic acid (DHA) are neuroprotec-
tive [6, 7] and have been suggested in cognitive decline pre-
vention [6], we did not include them in this review because
their suggested intake (around 500 mg/day, see ISSFAL.org
for example) does not classify them as Bmicro^ nutrients.
Alzheimer’s Disease—Etiological Summary
AD is an irreversible neurodegenerative disorder which stems
from the interaction between multiple factors that induce pro-
gressive memory loss and cognitive decline, exacerbated by
neurotransmitter deficits. Neuropathologically, AD is charac-
terized by the presence of extracellular senile plaques contain-
ing amyloid β peptides (Aβ) and intracellular neurofibrillary
tangles of hyperphosphorylated tau protein [8]. The Aβ pep-
tide is formed from amyloid protein precursor (APP) by se-
quential enzymatic processing, in which differentβ-secretases
and γ-secretase are involved [9]. Moreover, Aβ aggregations
are also tightly linked to increased oxidative stress. Oxidative
stress is accompanied by mitochondrial dysfunction, pro-
nounced inflammation, gliosis, axonal degeneration, and im-
pairment of synaptic transmission that ultimately end in pro-
gressive neuronal loss, predominantly by apoptosis [10]. In
summary, AD is a multifactorial disorder that must be ad-
dressed via a multidisciplinary approach, including proper nu-
trition and/or supplementation.
Vitamin C and AD
Vitamin C or ascorbic acid (AA) is a powerful water-soluble
antioxidant present mainly in citrus fruits, strawberries, kiwis,
and some green leaf vegetables such as spinach and broccoli.
It is an essential nutrient for humans given that we are inca-
pable of producing the enzyme gulonolactone oxidase needed
to synthesize AA from glucose [11]. Of note, a plethora of
biochemical processes are dependent on AA, particularly in
the brain that is able to store AA in great amounts. In fact, only
the adrenal glands contain similar concentrations of AA. AA
plays critical roles in brain development and myelin formation
[12], actively participates in the synthesis of neurotransmitters
such as enzyme cofactors, and it is one of the most potent
antioxidant agents in the organism [13, 14]. It should be noted
that AA could represent an excellent therapeutic candidate in
those neurodegenerative disorders characterized by increased
oxidative stress such as AD. Some AD animal studies have
been carried out in order to elucidate the mechanisms by
which AA affects cognitive function and neurodegeneration.
Murakami et al. [15] showed that AA attenuates Aβ oligo-
merization in APP transgenic mice. Likewise, Harrison et al.
[16] observed that short-term high-dose AA infusion
(125 mg/kg) in APP/PSEN1 and wild-type mice modifies
behavior, favoring spatial learning and memory. Currently, a
study—carried out in an AD mice model that is unable to
produce its own AA—reported that a high AA dose decreases
amyloid plaques burden in cortex and hippocampal brain of
these mice. Therefore, this suggests that AA could protect
against AD [17].
Along the same lines, numerous studies have reported that
AD patients show low plasma concentrations of AA [18].
Thus, the majority of clinical trials have focused on assessing
whether there is a true relationship between AA deficiency
and risk of developing AD. Some such trials reported negative
correlations between plasma AA levels and grade of decline
cognitive. However, other studies proposed that plasma AA
levels are not associated with age-related cognitive impair-
ment [19, 20]. This discrepancy might be due to several rea-
sons. First, plasma AA levels are dependent on daily intake,
and thus, they are not truly representative of long-term con-
sumption [21]. Second, although AA is highly concentrated in
the brain, there is no association between AA brain content
and plasma levels, at least according to spectroscopic assays
withMRI imaging [22], a non-invasive technique. Third, there
are genetic (e.g., carriers of AA expression) and non-genetic
(e.g., age) factors that modulate AA absorption and assimila-
tion in subsets of the population [23, 24]. This could explain
why during recruitment, some control participants without
signs of clinical scurvy actually exhibited AA deficiency ac-
cording to plasma levels.
Hence, keeping in mind the aforementioned, many publi-
cations suggested that AA supplements might decrease the
risk of developing AD or treat it altogether [25, 26]. Yet,
another subset of assays found no relationship between the
intake of vitamin C from food or supplements and reduced
likelihood to develop AD [27]. Moreover, Gu et al. [28] re-
ported that AA intake does not affect plasma Aβ levels or its
related mechanism. Therefore, the available literature about
the beneficial effects of diet supplementation with AA for
preventing or treating AD is inconclusive.
Furthermore, in order to understand the precise role of AA
in AD, we would need to carry out more clinical trials, paying
more attention to their design and to the recruitment of partic-
ipants, e.g., based on basal AA levels. Also, future assays
should consider AA levels in CSF rather than plasma as a
more important marker of AD.
Vitamin B and AD
B vitamins are a group of eight water-soluble vitamins that
control a great variety of metabolic activities [29, 30]. Al-
though their names are similar, all of them are chemically very
distinct. The main dietary sources of this group of vitamins are
meats, legumes, whole grains, potatoes, bananas, chili pep-
pers, and a wide catalogue of unprocessed products. However,
it is important to note that vitamin B12 (aka cobalamin) is not
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present in plant foods [29]. In this review, we focus on the role
of folate and vitamin B12 in AD. Folate is the most important
methyl group donor for maintaining integrity of DNA and
mitochondrial DNA, and vitamin B12 acts as cofactor in meth-
ylation and DNA synthesis. Hence, multiple acceptors are
methylated through the folate- and vitamin B12-dependent
methionine-homocysteine cycle [31, 32]. Deficiency of these
vitamins triggers neurological disorders such as memory loss,
cognitive impairment, neuropathy, myelopathy, and sensory
neuropathy [33]. It is well-known that increased homocyste-
ine levels in serum or urine are markers of folate and vitamin
B12 deficiency [34]. Homocysteine is a non-protein amino
acid, which derives from methionine metabolism as regulated
by B vitamins. Hyperhomocysteinemia (HHcy) impairs DNA
and mitochondrial DNA, causing oxidative stress and ROS
production as well as increased cytosolic calcium, which in-
duce neuronal death [35]. Recent clinical trials have reported
that HHcy is involved in cognitive decline and the develop-
ment of AD [36, 37]. Therefore, understanding the mecha-
nism(s) responsible for the association between HHcy and
AD could provide practical means to prevent or reduce the
risk of AD development. Zhang et al. [38] reported augmented
amyloidogenesis following direct injection of homocysteine
into animal brains. A recent study has demonstrated that a
folate-, vitamin B6-, and B12-deficient diet induces HHcy in
an AD-like mouse model and is associated with a significant
acceleration of their amyloidotic phenotype [39]. Further-
more, it would be expected that an intervention with diets
supplemented with folate or vitamin B12 could prevent o de-
crease the risk of developing AD. Accordingly, Haan et al.
[40] suggested that the risk of homocysteine-induced demen-
tia or cognitive decline might be modified by vitamin B12
supplementation. A small subset of dementias that are revers-
ible with vitamin B12 has been observed, and it must be
underscored that this treatment is inexpensive and safe [41].
However, the majority of clinical trials seem to indicate that
vitamin B12 intervention does reduce homocysteine concen-
trations, but that this does not lead to any benefit in terms of
cognition even after long-term of supplementation [42]. In
summary, accumulated evidence indicates that vitamin B12
therapy does not improve cognition in patients without
preexisting deficiency. Likewise, trials of folic acid supple-
mentation, either alone or in combination with other B vita-
mins, reported limited or no effect on measures of cognitive
function [43]. Of note, the observed discrepancy might be due
to short treatment periods, because degenerative processes
often take several years before the first symptoms appear.
Therefore, we would need to recruit patients with severe vita-
min B12 or folate deficiency. Also, we need to consider that
the doses of folate and vitamin B12 should lead to serum con-
centrations that greatly exceed normal values in order to ob-
serve some effect. This is of particular concern in the elderly,
where cobalamin is poorly absorbed [29], leading to acquired
vitamin B12 deficiency and marginal status in this population
subset. Thus, appropriate strategies to monitor B12 status and
increase its absorption should be implemented.
In conclusion, further intervention studies in large samples
with extended periods of follow-up are required. This will
allow for further investigation of the role of vitamin B12 or
folate in the onset or progression of AD.
Vitamin A and AD
Vitamin A or retinol is a lipophilic micronutrient present in
many foods from both vegetal and animal origins. In particu-
lar, adequate consumption of carrots, broccoli, pumpkin, dairy
products, liver, and eggs provides the recommended daily
allowance of vitamin A, i.e., 900 μg (3000 IU) for men and
700 μg (2300 IU) for women. Nevertheless, vitamin A can
also be synthetized in the brain [44]. Vitamin A is also named
retinol because it participates in the synthesis of retinal pig-
ments, which are essential for eyesight. Retinoid is a generic
term that includes vitamin A and its natural as well as synthet-
ic analogs. Awide range of biological activities and processes
are modulated by retinoids which bind to two classes of nu-
clear receptors, namely retinoic acid receptors and retinoid ×
receptors. The brain expresses various isoforms of these re-
ceptors [45]. Accumulated evidence demonstrates that reti-
noids play an important role in processes strongly related to
AD such as production of amyloid beta, inflammation, neuro-
transmission, and neurogenesis [46]. In addition, the synthesis
of retinoid acid is inhibited by the amyloid beta peptide, thus
exacerbating AD pathology [47]. Some authors have shown
that vitamin A possesses antioxidant, neuronal-protective, and
antioligomeric effects in in vitro and in vivo models of AD
[48]. In the same way, disruption of the retinoid-signaling
pathway in adult rats caused an accumulation of amyloid beta
in the brain [49]. Moreover, vitamin A deficiency induces a
downregulation of retinoid receptors, impairing short- and
long-term memory and even potentiating depression in mice
[50]. Likewise, preclinical studies of retinoids in transgenic
mouse models of AD showed that retinoic acid decreased
activation of microglia and astrocytes and improved spatial
learning and memory [51]. Vitamin A-deprived mice showed
a loss of hippocampal long-term potentiation, which was fully
reversible by standard diet or direct administration of retinoic
acid [52]. Thus far, all studies seem to support the hypothesis
that vitamin A is an important molecule in the prevention and
therapy of AD.
Lopes da Silva et al. [53] have demonstrated that these
differences are due to the fact that the AD and control popu-
lations presented different nutritional status when they were
recruited. However, when this difference is taken into consid-
eration, AD patients exhibited significantly lower vitamin A
status with respect to the control cohort. Theoretically, thera-
pies with retinoids could be used to mitigate the vitamin A
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deficit and, in turn, prevent AD. Along these lines, numerous
preclinical studies carried out in mouse models of AD showed
that administration of all-trans retinoic acid (ATRA) decreases
amyloid accumulation and tau hyperphosphorylation and im-
proves cognitive decline by gene expression modulation of
different molecules involved in these activities [51, 54]. Sim-
ilar observations have been reported with tamibarotene (AM-
80) and acitretin, synthetic retinoid acid analogs which upreg-
ulated ADAM10, an enzyme implica ted in non-
amyloidogenic processing of APP [55]. Several phase II clin-
ical trials (NCT01120002 and NCT01078168 clinical
trials.gov identifier) are ongoing, in order to test the effects
of retinoids in patients with AD. However, it should be
underscored that the administration of retinoids may trigger
some adverse reactions in certain patients. ATRA is extremely
toxic at its chemotherapeutic dose of 45 mg/m2/day, even at
90 days after treatment initiation; therefore, its use is limited in
older populations, who are—however—more prone to devel-
op AD. Moreover, prolonged retinoid usage produces gastro-
intestinal hemorrhage and abdominal pain [55], and extreme
caution must be exerted.
In conclusion, the evidence available from preclinical stud-
ies shows that retinoids possess antiapoptotic, antioxidant,
pro-differentiative, antiamyloidogenic, and antiinflammatory
activities. Thus, vitamin A and its analogs might be consid-
ered as potential candidates for AD therapy. Yet, more clinical
trials and toxicity assays are needed to elucidate the therapeu-
tic role of vitamin A in AD.
Vitamin D and AD
Vitamin D belongs to the group of fat-soluble vitamins and is
responsible for the intestinal absorption of various ions. It is
also involved in calcium homeostasis and metabolism. Vita-
min D is chiefly synthesized in the skin, following exposure to
sunlight. In fact, fish and eggs are only foods that contain a
vitamin D in noteworthy concentrations. Vitamin D from cu-
taneous synthesis and dietary intake is activated by hydroxyl-
ation in liver and kidney, producing 1,25-dihydroxyvitamin D
that is the main circulating metabolite of vitamin D [56]. This
molecule executes its functions by binding to its vitamin D-
specific receptor. Many studies have reported that vitamin D
presents a high affinity to this receptor in several brain regions
and different cellular types; also, it has been demonstrated that
the vitamin D receptor is widespread in the human brain. As
an example, Eyles et al. described the existence of vitamin D
receptors in the hippocampus, one of the main brain regions
affected by AD [57]. Further, vitamin D signaling is involved
in brain developing and function.
On the other hand, it is well known that the elderly are at a
high risk of developing vitamin D deficiency due to decreased
cutaneous synthesis [58] and dietary intake [59]. However, the
intestinal absorption of vitamin D is not affected by age [60].
Until date, many clinical trials have found a strong association
between low vitamin D concentrations and an increased risk
of all-cause dementia and AD. All authors agree that vitamin
D supplementation might have protective effects [61, 62].
Preliminary in vitro studies showed that vitamin D increases
clearance and Aβ phagocytosis by macrophages of AD pa-
tients and reduces amyloid-induced cytotoxicity and apoptosis
in primary cortical neurons [63]. The administration of 1,25-
dihydroxyvitamin D decreases cerebral Aβ accumulation and
improves cognition in mouse models of AD [64]. Based on
these findings, several clinical trials have been carried out to
evaluate the effects of vitamin D supplementation on cogni-
tion in elderly patients. The results obtained thus far are con-
troversial, as there is discrepancy about the methods used to
evaluate cognition decline, the treatment period, and doses
and form of vitamin D: The literature shows that vitamin D3
is more bioavailable than vitamin D2. Furthermore, some au-
thors suggest treating older patients with higher dose of vita-
min D in order to ascertain if there is any neuroprotective
effect of this vitamin [65]. Hence, more clinical trials should
be carried out in order to confirm whether vitamin D supple-
mentation could be used to delay or prevent the onset of AD in
older adults.
Vitamin E and AD
Vitamin E was first described by Evans and Bishop [66]
as a family of lipid-soluble compounds that encloses four
tocopherols and four tocotrienols: α (alpha), β (beta), γ
(gamma), and δ (delta): All of them are referred to as
vitamin E. The tocopherols are saturated forms of vitamin
E, whereas the tocotrienols are unsaturated and possess an
isoprenoid side chain. α-Tocopherol is the most abundant
biologically active form in nature [67]. The majority of
vegetable oils are rich in all four tocopherol forms in
different proportions, and tocotrienols are found in certain
cereals and seeds such as wheat germ, oats, hazelnuts,
maize, sunflower seeds and palm oil, rice bran oil, and
poppy seed oil [68]. Numerous studies have shown the
antioxidant properties of the vitamin E in a large variety
of pathologies such as cancer, cardiovascular, and neuro-
degenerative alterations [69–71]. Vitamin E is able to
scavenge free radicals converting them in less reactive
compounds, favoring the cells’ normal function. However,
recent studies have demonstrated that vitamin E also pos-
sesses important activities non-related to its antioxidant
activity [72]. Vitamin E inhibits or activates several en-
zymes involved in different signaling cascades and also
modulates the expression of some genes [73]. Moreover,
some v i t amin E fo rms have been a t t r i bu t ed
antiinflammatory effects [74]. Therefore, its ample array
of biological activities could explain, in part, the beneficial
effects of vitamin E on various pathologies whose
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triggering agents are totally different. In this review, we
focus on the effects of vitamin E in Alzheimer’s disease.
It is widely accepted that the extracellular deposits of am-
yloid beta peptide and neurofibrillary intracellular tangles
of hyperphosphorylated tau protein are the foremost etio-
logical agents of AD. A recent study described how vita-
min E prevents the activation of p38MAPK, whose activ-
ity is essential for phosphorylation of neuronal tau mole-
cules [75]. In the last decade, the combination of in vitro
and in vivo experiments has suggested a protective anti-
oxidant role of vitamin E in the AD context [76]. Admin-
istration of vitamin E encapsulated into nanospheres de-
creases levels of amyloid beta-induced reactive oxygen
species in the SH-SY-5Y human neuroblastoma cells
[77]. Also, this vitamin protects against the oxidation-
mediated decrease of synaptic proteins involved in neuro-
transmission, hence delaying cognitive decline [78]. Addi-
tionally, in vivo studies of AD are suggesting that vitamin
E modulates the abnormal inflammatory response associat-
ed to this disease [79]. Nevertheless, apart from antioxi-
dant and antiinflammatory properties, other studies have
attributed certain antiamyloidogenic actions to vitamin E,
because it decreased Aβ levels and the global volume of
senile plaques in the early stages of AD [80]. According
to Huebbe et al., α-tocopherol is able to modulate amyloid
precursor protein processing by regulating mRNA concen-
trations of secretase enzymes [81]. Therefore, when con-
sidering these studies, we can postulate that vitamin E
might be useful in treating AD based on its beneficial
properties here described. In consonance with this conclu-
sion, it has been shown that long-term feeding of rats with
a diet supplemented with vitamin E protects against age-
related cognitive decline [82]. However, this conclusion
has not been undoubtedly confirmed by current clinical
trials. If any, all of the clinical evidence obtained thus
far concedes that there is an inverse correlation between
vitamin E plasma concentrations and progression rate of
AD [18]. Therefore, it is reasonable to expect that a diet
enriched or supplemented with vitamin E would improve
cognitive impairment or its progression to AD. A prospec-
tive study from Morris and colleagues reported that indi-
viduals with higher vitamin E intake from diet and sup-
plements showed reduced cognitive decline and risk of
developing AD when compared to control, i.e., low vita-
min E intake individuals [83]. In a similar study, the au-
thors recorded a lower risk of developing AD in individ-
uals consuming foods rich in vitamin E [26]. Likewise, a
cohort study evaluated the relationship between AD and
the plasma concentrations of all vitamin E forms; the au-
thors reported an association between low plasma tocoph-
erol and tocotrienol levels and increased probability to
develop AD [83]. Indeed, epidemiological studies report
that vitamin E from food sources, i.e., the more
bioavailable [84] natural form is more effective at
preventing age-related neurodegenerative disorders than di-
etary supplementation [85]. Congruently, several clinical
trials have indicated that vitamin E supplementation has
no beneficial effects against cognitive impairment or the
progression to AD [86, 85]. In brief, there appears to be
some discrepancy about the putative beneficial effects of
vitamin E in patients with AD. Some explanations have
been proposed to explain, in part, these controversial re-
sults. Firstly, the criteria to recruit patients with AD are
different among the various clinical trials. The vitamin E
dose, period of treatment, and the tests employed to eval-
uate cognitive impairment are very variable between the
different trials. Further, in majority of trials, vitamin E
supplements were α-tocopherol and the other forms have
not been not employed. A recent study has demonstrated
that tocotrienols are more potent radical scavengers than
α-tocopherol [68]. It has also demonstrated that γ-
tocopherol has greater antiinflammatory property than α-
tocopherol [87]. Consequently, the inconclusive results ob-
tained from clinical trials might be partly due to the fact
that the investigators did not take into consideration these
aspects. One final issue that deserves attention is the fact
that the systemic antioxidant actions of vitamins E and C
have never been clearly demonstrated in humans; there-
fore, we should be careful when we attribute the purported
beneficial effects of these vitamins to mere antioxidant
activities.
In conclusion, additional clinical trials should be carried
out with other forms of vitamin E in order to elucidate its
potential beneficial properties toward AD treatment and
prevention.
Vitamin K and AD
Vitamin K belongs to the fat-soluble vitamin group. There
are two biologically active forms (K1 and K2) and other
synthetic analogs (K3, K4, and K5). Vitamin K1
(phylloquinone) is the most common form of vitamin K
and is present in several plants, especially in leaf vegeta-
bles, certain vegetable oils, and in fruits, tubers, and seeds.
Vitamin K2 or menaquinone occurs in animal products
such as meat, eggs, cheese, and curd [88]. With respect
to its analogs, vitamin K3 or menadiones is a synthetic
molecule used to treat vitamin K deficiency and as food
supplement [88, 89]. All these forms of vitamin K possess
antihemorrhagic property and participate in bone metabo-
lism [90], even though other novel pharmacological and
therapeutic activities have been discovered in recent years,
including antioxidant and repressor of vascular calcifica-
tion and neurological disorders associated to aging. Like-
wise, Allison has been the first one who reported that
vitamin K deficiency is associated with AD pathogenesis,
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because—in that study—plasma concentrations of vitamin
K were lower in patients with a high genetic risk factor
for developing AD than in healthy patients with the same
age [91]. Of note, vitamin K deficiency promotes collagen
mineralization in the intima and, thus, loss of vasomotion
[92]. A recent clinical trial found that patients with early
stage Alzheimer’s disease consumed less vitamin K than
did cognitively intact control subjects, which explains the
vitamin K deficiency recorded in these patients [93]. Ad-
ditionally, other studies have demonstrated that such
hypovitaminosis is related to the greater prevalence of
hip fractures observed in patients with AD [94]. Finally,
in vitro and spectrometric assays have demonstrated that
vitamin K3 analogs inhibit Aβ aggregation and protect
cells against Aβ-induced cytotoxicity [95]. Hence, acces-
sible evidence is indicating that vitamin K could play a
pivotal role in AD; there is also no current evidence that
long-term administration of vitamin K produces undesir-
able effects. The efficacy of exposure to sunlight and of
a diet supplemented with calcium, vitamin K2, and vitamin
D against hip fractures—which afflict AD patients—has
been demonstrated [96], even though it is impossible to
ascertain the individual contr ibutions of these
micronutrients. Further, no clinical trials assessed the po-
tential antiamyloidogenic effects of vitamin K in patients
with AD, notably in their quintessential cognitive decline.
In summary, vitamin K appears to be a promising agent in
AD therapy, but more in vitro and in vivo studies together
with appropriate clinical trials should be carried out to
discern the true role of this molecule as a viable treatment
of AD.
(Poly)phenols and AD
In addition to vitamins, humans also eat fairly large amounts
of (poly)phenols, which might play some healthful roles on
neurodegenerative disorders [97]. Some of these compounds
indeed improve certain pathologic features of AD in animal
models, likely because of their mitochondria-augmenting ac-
tivities [97]. (Poly)phenols from different fruits and beverages
such as blueberries, grapes, apples, turmeric, green and black
teas, wine, coffee, and cocoa possess multiple health activities,
which may—theoretically—reduce the risk of AD [97]. It has
been reported that phenolic compounds from bilberry and
blackcurrant extracts possess antiamyloidogenic activity and
alleviate behavioral abnormalities in a mouse model of AD
[98]. Also, antiinflammatory properties have been granted to
apple and green tea beverages, because they decrease pro-
inflammatory cytokine levels in initial phase or moderate
phase AD patients [99]. Tea, whether green or black, is rich
in (poly)phenols endowed with in vitro antioxidant activities,
which have been suggested to explain their putative neuropro-
tective actions. Nonetheless, other properties have been
attributed to such neuroprotective and antiamyloidogenic
(poly)phenols [100, 101].
Several epidemiological reported a reduction of dementias
and Alzheimer’s risk associated with moderate alcohol use, as
compared with abstainers, with extents of risk reduction that
vary among studies and meta-analyses [102]. Mechanistically,
ethanol is able to reduce synaptic damage induced by beta-
amyloid and synuclein [103]. Also, some in vitro studies re-
ported that resveratrol possesses antiamyloidogenic activity,
reducing the level of secreted or intracellular Aβ peptides
[104]. Moreover, this (poly)phenol is able to reduce—still
in vitro—the oxidative stress typical of AD, by reducing neu-
ronal death and suppressing activation of astrocytes and mi-
croglia [105]. Despite these encouraging in vitro data, it is
very unlikely that resveratrol is responsible for the preventive
activities of wine, because (1) wine contains resveratrol in
trace amounts [102]; (2) risk reduction is not exclusive to wine
and is seen across all alcoholic beverages [102]; and (3) res-
veratrol is not bioavailable and its human activities are ques-
tionable to say the least [106, 107].
Another (poly)phenol-rich food item that is attracting at-
tention is turmeric, whose rhizome contains the yellow pig-
ment curcumin, which is used as food preservative and spice.
Substantial in vitro evidence indicates that curcumin has
antiamyloidogenic, antioxidant, and antiinflammatory proper-
ties, all of which suggest its potential to prevent AD [108].
Frautschy et al. [109] suggested that curcumin might prevent
Aβ-mediated synaptic deficits, because curcumin-fed/Aβ-
injected rats exhibited better memory function compared to
Aβ-injected rats. Again, curcumin is poorly bioavailable,
and its human activities remain to be fully proven.
Along the same lines of research, coffee, a complex mix-
ture of (poly)phenolic components, diterpenes and caffeine,
might possess beneficial effects on cognitive and neurological
health. Some preclinical studies have demonstrated that
chlorogenic acid, the main phenol present in coffee [110],
prevents Aβ-induced oxidative stress and exerts neuroprotec-
tive effects by inhibiting overactivated neuronal enzymes re-
sponsible for the hydrolysis of neurotransmitters [111, 112].
Likewise, clinical studies suggest that chlorogenic acid sup-
plementation could protect against cognitive degeneration
[113]; however, no formal and well-controlled studies have
been performed to date to confirm or disprove this hypothesis.
Also, it is currently very difficult to discriminate the effects of
coffee (poly)phenols such as chlorogenic acid from those of
caffeine. In synthesis, the evidence pro or against neuropro-
tective effects of coffee intake is still inconsistent [114].
Finally, cocoa and chocolate contain (poly)phenols in co-
pious amounts, together with some other compounds with
potential biological activity [115]. It has been shown that
polyphenols from cocoa interact with signalization cascades
that lead to the inhibition of neuronal death by apoptosis and
promote neuronal survival and synaptic plasticity [116]. In
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addition, cocoa preserves murine cognitive abilities during
aging, lowering the risk of developing AD [117]. It has been
suggested that cocoa (poly)phenols activates the brain-derived
neurotrophic factor (BDNF) survival pathway because of their
antioxidant properties [116]. One aspect that needs elucidation
is when consumption of cocoa and chocolate should be initi-
ated to generate beneficial effects (if any) on age-dependent
cognitive decline and neurodegenerative diseases [118].
It is noteworthy that no human intervention studies of green
and black tea, wine (poly)phenols, curcumin, or cocoa in AD
have been reported. Therefore, the extrapolation of in vitro
and in vivo (animals) studies to the human situation still re-
quires properly designed clinical trials.
Conclusions
Age-related cognitive decline is one of the major health
challenges we are facing. Indeed, life expectancy is con-
stantly increasing worldwide, which provokes major social
imbalances as well as an increased burden on the national
health care systems. There are currently no viable pharma-
cological tools to treat cogitive decline; therefore, several
multidisciplinary preventive approaches to this disorder are
being developed. Certainly, the implementation of correct
diets and/or the use of adequate supplements appears of
paramount importance in the elderly. Nevertheless, there
are very few controlled and good-quality studies address-
ing the variegated effects of some dietary or pharmacolog-
ical agents on mild cognitive decline and neurodegenera-
tion as associated with age. In the case of micronutrients
(as reviewed here), most of the available evidence comes
from epidemiological and in vitro studies and clearly un-
derscores the need to follow healthful diets and proper
lifestyles, starting early in life. While attention is habitual-
ly paid to the macronutrient profile of diets and to caloric
intake, emphasis should also be placed on essential fatty
acids and micronutrients, namely vitamins and polyphe-
nols, whose role appears to be crucial in AD prevention.
Also, we might need to emphasize the potential preventive
activities of some micronutrients in other forms of cogni-
tive decline: Conceivably, milder forms might benefit the
most from proper micronutrient intake.
One unresolved issue is whether lower serum concen-
tration of several nutrients is due to disease-specific
mechanism or due to the often poor nutritional intake
and thus status of AD/dementia patients (or both). Yet,
we still need properly executed clinical trials with reli-
able markers of cogitive decline; however, the possibility
to formulate evidence-based nutraceuticals/supplements/
functional foods targeted at the elderly should find a
pertinent place in the Bhealthy aging^ decalogue.
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